ATE195878T1 - Toxine und toxoide von clostridium difficile als schleimhautadjuvans - Google Patents

Toxine und toxoide von clostridium difficile als schleimhautadjuvans

Info

Publication number
ATE195878T1
ATE195878T1 AT96923569T AT96923569T ATE195878T1 AT E195878 T1 ATE195878 T1 AT E195878T1 AT 96923569 T AT96923569 T AT 96923569T AT 96923569 T AT96923569 T AT 96923569T AT E195878 T1 ATE195878 T1 AT E195878T1
Authority
AT
Austria
Prior art keywords
toxoids
toxins
clostridium difficile
adjuvant
mucous
Prior art date
Application number
AT96923569T
Other languages
English (en)
Inventor
William D Thomas Jr
Thomas P Monath
Zhenxi Zhang
Francisco Javier Torres-Lopez
Wende Lei
David M Lyerly
James S Moncrief
Original Assignee
Oravax Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27053134&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE195878(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/543,708 external-priority patent/US5919463A/en
Application filed by Oravax Inc filed Critical Oravax Inc
Application granted granted Critical
Publication of ATE195878T1 publication Critical patent/ATE195878T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT96923569T 1995-07-07 1996-07-01 Toxine und toxoide von clostridium difficile als schleimhautadjuvans ATE195878T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US49938495A 1995-07-07 1995-07-07
US08/543,708 US5919463A (en) 1995-07-07 1995-10-16 Clostridium difficle toxins as mucosal adjuvants
PCT/US1996/011142 WO1997002836A1 (en) 1995-07-07 1996-07-01 Clostridium difficile toxins as mucosal adjuvants

Publications (1)

Publication Number Publication Date
ATE195878T1 true ATE195878T1 (de) 2000-09-15

Family

ID=27053134

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96923569T ATE195878T1 (de) 1995-07-07 1996-07-01 Toxine und toxoide von clostridium difficile als schleimhautadjuvans

Country Status (9)

Country Link
EP (1) EP0837692B1 (de)
JP (1) JPH11509200A (de)
CN (1) CN1195297A (de)
AT (1) ATE195878T1 (de)
AU (1) AU720567B2 (de)
CA (1) CA2226339A1 (de)
DE (1) DE69610106D1 (de)
NZ (1) NZ312502A (de)
WO (1) WO1997002836A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9626864D0 (en) * 1996-12-24 1997-02-12 Smithkline Beecham Biolog Vaccine
AU746859B2 (en) * 1997-06-20 2002-05-02 Imperial College Of Science, Technology And Medicine Immonogenic fragments of toxin a of clostridium difficile
EP1568378B1 (de) * 1997-10-20 2016-03-16 Sanofi Pasteur Biologics, LLC Immunisierung gegen Clostridium difficile Krankheit
EP2305303A3 (de) * 1997-10-20 2013-11-13 Sanofi Pasteur Biologics Co. Immunisierung gegen Clostridium difficile-Erkrankung
US6969520B2 (en) 1997-10-20 2005-11-29 Acambis Inc. Active immunization against clostridium difficile disease
WO1999049890A1 (en) * 1998-03-31 1999-10-07 Daewoong Pharmaceutical Co., Ltd. A preventive and therapeutic vaccine for helicobacter pylori-associated diseases
WO2000061761A2 (en) * 1999-04-09 2000-10-19 Techlab, Inc. Recombinant clostridium toxin a protein carrier for polysaccharide conjugate vaccines
US6733760B1 (en) 1999-04-09 2004-05-11 Techlab, Inc. Recombinant toxin A/toxin B vaccine against Clostridium difficile
EP1169456B1 (de) * 1999-04-09 2012-07-11 Intercell USA, Inc. Rekombinante Herstellung vom Toxin A oder Toxin B der Clostridium difficile
WO2011126811A2 (en) 2010-03-30 2011-10-13 Pfenex Inc. High level expression of recombinant toxin proteins
KR101907434B1 (ko) 2010-09-03 2018-10-12 발네바 오스트리아 게엠베하 C. 디피실의 a 독소 및 b 독소 단백질의 분리된 폴리펩타이드 및 이의 용도
AR086199A1 (es) 2011-04-22 2013-11-27 Wyeth Llc Composiciones relacionadas con una toxina de clostridium difficile mutante y sus metodos
US9290565B2 (en) * 2011-05-27 2016-03-22 Glaxosmithkline Biologicals, S.A. Immunogenic composition
AU2012349753A1 (en) 2011-12-08 2014-06-19 Novartis Ag Clostridium difficile toxin-based vaccine
BR122016023101B1 (pt) 2012-10-21 2022-03-22 Pfizer Inc Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile
WO2021255690A2 (en) 2020-06-19 2021-12-23 Pfizer Inc. Immunogenic compositions against clostridioides (clostridium) difficile and methods thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4944942A (en) * 1987-08-27 1990-07-31 Mobay Corporation Intranasal vaccination of horses with inactivated microorganisms or antigenic material
JP2849632B2 (ja) * 1988-04-08 1999-01-20 社団法人北里研究所 ワクチン製剤
US5601823A (en) * 1989-10-31 1997-02-11 Ophidian Pharmaceuticals, Inc. Avian antitoxins to clostridium difficle toxin A
AU4773293A (en) * 1992-07-16 1994-02-14 Oxford University Multiple particulate antigen delivery system
GB9305919D0 (en) * 1993-03-22 1993-05-12 Health Lab Service Board Botulinum toxin polypeptides and their use as vaccines

Also Published As

Publication number Publication date
AU6404796A (en) 1997-02-10
AU720567B2 (en) 2000-06-08
JPH11509200A (ja) 1999-08-17
CN1195297A (zh) 1998-10-07
CA2226339A1 (en) 1997-01-30
NZ312502A (en) 1999-03-29
EP0837692B1 (de) 2000-08-30
EP0837692A4 (de) 1998-04-29
WO1997002836A1 (en) 1997-01-30
EP0837692A1 (de) 1998-04-29
DE69610106D1 (de) 2000-10-05

Similar Documents

Publication Publication Date Title
DE69610106D1 (de) Toxine und toxoide von clostridium difficile als schleimhautadjuvans
Sesardic et al. Detection of antibodies against botulinum toxins
DE68924162D1 (de) Stressproteine und verwendungen dafür.
TR199801722T2 (xx) Peptit imm�nojenler.
TR200403064T2 (tr) Tüberkülozun teşhisi ve immünoterapi yolu ile önlenmesine mahsus yöntemler ve bileşikler.
DE69327534D1 (de) Impfstoffe gegen diphtherietoxin
EP0762892A4 (de) Diphtheria toxin impfstoffe mit mutierter r domäne
IL132468A0 (en) A kit for inducing immune response against a tumor or a disease caused by an infection agent
ATE198051T1 (de) Pneumokokken-polysaccharid-rekombinante- pneumolysin-konjugate als impfstoffe für die immunisierung gegen pneumokokken-infektionen
TR200102497T2 (tr) Yeni streptococcus antijenleri
DK0618813T3 (da) Antigen for M-hybridprotein og bærer for gruppe A streptococcal vaccine
DE69324487D1 (de) Rezeptorbindende region des diphtherietoxius
DE69738138D1 (de) Induktion von immunologischer Toleranz gegen einen therapeutischen Antikörper durch Varianten des therapeutischen Antikörpers
DK0858504T3 (da) Diagnostiske midler mod og behandlinger af periodontale sygdomme
ATE220688T1 (de) Tumor-zerstörende effekte von enterotoxinen und verwandten verbindungen
WO1994010317A3 (en) Conjugate vaccine against group b streptococcus
ATE157259T1 (de) Verbesserte adjuvantien und impfstoffe
HUP9801223A2 (hu) Eljárás specifikus antigénekre adott antitest válasz fokozására interleukin-10-zel
Stephano et al. The improvement of the therapeutic anti-Lachesis muta serum production in horses
PT946730E (pt) Mutantes de toxina estreptococica c e metodos de utilizacao
JPH08511508A (ja) ボツリヌス毒素ポリペプチドおよびワクチン増強剤としてのその使用
DE69928523D1 (de) Verotoxin b untereinheit zur immunisierunug
ES2236692T3 (es) Un metodo para prevenir los efectos secundarios y la insensibilidad a los usos terapeuticos de toxinas.
DK0623170T3 (da) Vacciner baseret på streptokinase
AU6176596A (en) Compositions exhibiting adp-ribosyltransferase activity and methods for the preparation and use thereof